Abstract
Abstract Introduction/Background The use of nanomaterial-based therapeutic systems is rapidly growing and covering several biomedical applications such as detection, diagnosis and treatment. Recently, nanodiamonds (NDs) have been demonstrated to have great potential as a multimodal imaging/therapy platform. NDs are attractive for use in drug delivery because of their rich surface chemistry. NDs enhance the ability of the drug to cross the cell membrane, increase intracellular drug delivery to the cancer cells, improve treatment efficacy, and decrease toxicity to normal cells or tissues. Docetaxel (DTX) ‘a chemotherapeutic agent’ has very low neurotoxic effect to the cancer patients. Therefore, we hypothesized that targeting HER-3 positive ovarian cancer (OC) ex-vivo explants by loading NDs with DTX would improve drug targeting and delivery. Thus, we aimed to investigate the efficacy of ND-conjugated DTX on OC ex-vivo explants.